This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Faricimab intravitreal injection


Intravitreal injection of faricimab.

These products have been produced by recombinant technology using Chinese Hamster Ovary (CHO) cell lines.

Drugs List

  • faricimab 28.8mg/0.24ml solution for injection vial
  • VABYSMO 28.8mg/0.24ml solution for injection vial
  • Therapeutic Indications


    Treatment of neovascular age-related macular degeneration
    Treatment of visual impairment due to diabetic macular oedema


    Faricimab is intended for long-term treatment.


    6mg (0.05ml solution) every 4 weeks for the first 4 doses.

    Neovascular age-related macular degeneration (nAMD).
    An assessment of disease activity based on anatomic and/or visual outcomes is recommended 20 and/or 24 weeks after treatment initiation so treatment can be individualised. In patients without disease activity, administration of faricimab every 16 weeks should be considered. In patients with disease activity, treatment every 8 weeks or 12 weeks should be considered.

    Visual impairment due to diabetic macular oedema (DMO).
    Treatment may be individualised using a treat-and-extend approach following an assessment of the individual patient's anatomic and visual outcomes. The dosing interval may be extended from every 4 to every 16 weeks, with extensions in increments of up to 4 weeks, based on the physician's judgement of the individual patient's anatomic and/or visual outcomes. If anatomic and/or visual outcomes change, the treatment interval should be adjusted accordingly, and interval reductions of up to 8 weeks may be implemented if deemed necessary.


    For intravitreal use only.


    Children under 18 years
    Ocular infection
    Ocular inflammation
    Periocular infection
    Recent ocular surgery

    Precautions and Warnings

    Females of childbearing potential
    Risk factors for retinal pigment epithelial tears
    History of cerebrovascular disorder
    History of myocardial infarction
    History of transient ischaemic attack
    Uncontrolled glaucoma

    Suspend treatment if planned surgery within next 28 days
    Advise patient blurred vision may affect ability to drive/operate machinery
    Treatment to be prescribed and administered by a specialist
    Contains polysorbate
    Discard any unused portion
    Do not use if solution is discoloured or particulates are apparent
    Record name and batch number of administered product
    Monitor and manage perfusion of optic nerve head
    Monitor intra-ocular pressure post injection and manage appropriately
    Advise patient to report any symptoms of endophthalmitis immediately
    Advise patient to report any unexpected changes in eye symptoms immediately
    Discontinue if rhegmatogenous retinal detachment or stage 3/4 macular holes
    Suspend if best-corrected visual activity declines by 30 letters or more
    Suspend treatment if retinal break or tear develops
    Female: Contraception required during and for 3 months after treatment

    Arterial thromboembolic events (ATE's): Systemic adverse events including arterial thromboembolic events have been reported following intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors, including faricimab, and there is a theoretical risk that these may be related to VEGF inhibition.

    There is a potential for immunogenicity with faricimab. Patients should be instructed to inform their physician of any signs or symptoms of intraocular inflammation such as vision loss, eye pain, increased sensitivity to light, floaters or worsening eye redness, which may be a clinical sign attributable to hypersensitivity.

    Faricimab should not be administered concurrently with other anti-VEGF medicinal products (systemic or ocular).

    Pregnancy and Lactation


    Use faricimab with caution during pregnancy.

    The manufacturer advises that as a precautionary measure it is preferable to avoid the use of faricimab during pregnancy unless the potential benefit outweighs the potential risk to the fetus. At the time of writing, there is no or limited amount of data from the use of faricimab in pregnant women. Systemic exposure after ocular administration of faricimab is very low. Animal studies in pregnant cynomolgus monkeys did not indicate direct or indirect harmful effects with respect to reproductive toxicity including embryo-fetal development.


    Faricimab is contraindicated during breastfeeding.

    The manufacturer advises that a decision must be made whether to discontinue breastfeeding or to discontinue faricimab treatment taking into account the benefit of breastfeeding for the child and the benefit of therapy for the women. It is unknown whether faricimab is excreted in human milk. A risk to the breastfed infant/newborn cannot be excluded.

    Side Effects

    Abnormal vision
    Arterial thrombosis
    Blurred vision
    Conjunctival haemorrhage
    Conjunctival hyperaemia
    Corneal abrasion
    Eye disorder
    Eye irritation
    Eye pain
    Eye pruritus
    Increased intra-ocular pressure
    Increased lacrimation
    Ocular discomfort
    Ocular hyperaemia
    Ocular inflammation
    Reduced visual acuity
    Retinal detachment
    Retinal pigment epithelial tear
    Retinal tear
    Sensation of foreign body in eye
    Vitreous floaters
    Vitreous haemorrhage


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: August 2022

    Reference Sources

    Summary of Product Characteristics: Vabysmo 120mg/ml solution for injection. Roche Products Limited. Revised May 2022.

    NICE Evidence Services Available at: Last accessed: 22 August 2022

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.